Whit Richardson | TECH.CO
While it sounds straight out of a Sci-Fi novel, Kevin Strange (CEO and cofounder) and his cofounder, Viravuth Yin, along with another researcher, Michael Zasloff, have identified a certain molecule (it’s called MSI-1436) that has demonstrated regenerative properties in the laboratory, first in zebrafish and then in mice.
The goal now is to lead this drug candidate through clinical trials in large mammals and then, hopefully, demonstrate that it can help humans regenerate heart muscle tissue following a heart attack. Together they launched Novo Biosciences.
“That was pretty much a crackpot idea eight years ago, but in less than four years we made the discovery of a drug that launched Novo Biosciences,” Strange says. “To date, it’s the first and only drug that’s ever been shown to stimulate regeneration of the mammalian heart.”